Showing results (721-730 of 1,120) with videos related to
Sort By:
Pageof 112
JAMA Cardiology|March 30, 2017
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical TrialPatricia A Cowper, Shubin Sheng, Renato D Lopes, et al.Natural Product Research|July 10, 2015
Enhancement of the antibiotic activity of aminoglycosides by extracts from Anadenanthera colubrine (Vell.) Brenan var. cebil against multi-drug resistant bacteriaHumberto M Barreto, Kivia M R N Coelho, Josie H L Ferreira, et al.Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology|November 1, 2014
Light-mediated antibacterial activity of Lippia origanoides H.B.K. in vitroHumberto M Barreto, Bruno R C Coelho, Suellen M P Menezes-Silva, et al.Plos One|November 20, 2020
Validity of bioelectrical impedance to estimate fat-free mass in boys with Duchenne muscular dystrophyEvellyn C Grilo, Thais A Cunha, Ádila Danielly S Costa, et al.American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.American Heart Journal|July 22, 2020
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart ValveOliver K Jawitz, Tracy Y Wang, Renato D Lopes, et al.Journal of Cardiac Failure|July 21, 2023
Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical TrialsNathan P Goodwin, Robert M Clare, Josephine L Harrington, et al.Circulation|September 4, 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA TrialWilliam F McIntyre, Alexander P Benz, Jeff S Healey, et al.Diabetes Care|November 24, 2019
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL TrialM Angelyn Bethel, Robert J Mentz, Peter Merrill, et al.European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.Pageof 112